Φορτώνει......
Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition
Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insul...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Endocr Soc |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Endocrine Society
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6007247/ https://ncbi.nlm.nih.gov/pubmed/29942923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2017-00475 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|